Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

被引:4539
|
作者
Jaakkola, P
Mole, DR
Tian, YM
Wilson, MI
Gielbert, J
Gaskell, SJ
von Kriegsheim, A
Hebestreit, HF
Mukherji, M
Schofield, CJ
Maxwell, PH
Pugh, CW
Ratcliffe, PJ
机构
[1] Univ Oxford, Oxford OX3 7BN, England
[2] Univ Manchester, Inst Sci & Technol, Dept Chem, Michael Barber Ctr Mass Spectrometry, Manchester M60 1QD, Lancs, England
[3] Univ Oxford, Glycobiol Inst, Oxford OX1 3QU, England
[4] Univ Oxford, Dyson Perrins Lab, Oxford Ctr Mol Sci, Oxford OX1 3QY, England
关键词
D O I
10.1126/science.1059796
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Hypoxia-inducible factor (HIF) is a transcriptional complex that plays a central role in the regulation of gene expression by oxygen. In oxygenated and iron replete cells, HIF-alpha subunits are rapidly destroyed by a mechanism that involves ubiquitylation by the von Hippel-Lindau tumor suppressor (pVHL) E3 Ligase complex. This process is suppressed by hypoxia and iron chelation, allowing transcriptional activation. Here we show that the interaction between human pVHL and a specific domain of the HIF-1 alpha subunit is regulated through hydroxylation of a proline residue (HIF-1 alpha P564) by an enzyme we have termed HIF-alpha prolyl-hydroxylase (HIF-PH). An absolute requirement for dioxygen as a cosubstrate and iron as cofactor suggests that HIF-PH functions directly as a cellular oxygen sensor.
引用
收藏
页码:468 / 472
页数:5
相关论文
共 49 条
  • [41] Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1α, HIF-2α, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway
    Blancher, C
    Moore, JW
    Robertson, N
    Harris, AL
    CANCER RESEARCH, 2001, 61 (19) : 7349 - 7355
  • [42] Ca2+-activated K+ channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1α and the von Hippel-Lindau protein
    Tajima, N
    Schönherr, K
    Niedling, S
    Kaatz, M
    Kanno, H
    Schönherr, R
    Heinemann, SH
    JOURNAL OF PHYSIOLOGY-LONDON, 2006, 571 (02): : 349 - 359
  • [43] Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status
    Messai, Yosra
    Gad, Sophie
    Noman, Muhammad Zaeem
    Le Teuff, Gwenael
    Couve, Sophie
    Janji, Bassam
    Kammerer, Solenne Florence
    Rioux-Leclerc, Nathalie
    Hasmim, Meriem
    Ferlicot, Sophie
    Baud, Veronique
    Mejean, Arnaud
    Mole, David Robert
    Richard, Stephane
    Eggermont, Alexander M. M.
    Albiges, Laurence
    Mami-Chouaib, Fathia
    Escudier, Bernard
    Chouaib, Salem
    EUROPEAN UROLOGY, 2016, 70 (04) : 623 - 632
  • [44] Belzutifan, a hypoxia-inducible factor-2α ( HIF-2α) inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: Long-term results of the phase 2 LITESPARK-004 study
    Srinivasan, Ramaprasad
    Iliopoulos, Othon
    Beckermann, Kathryn E.
    Narayan, Vivek
    Maughan, Benjamin L.
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Iversen, Ane B.
    Cornell, Jerry
    Perini, Rodolfo F.
    Liu, Yanfang
    Linehan, W. Marston
    Jonasch, Eric
    CANCER RESEARCH, 2024, 84 (07)
  • [45] Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
    Srinivasan, Ramaprasad
    Donskov, Frede
    Iliopoulos, Othon
    Rathmell, Wendy Kimryn
    Narayan, Vivek
    Maughan, Benjamin L.
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah Joanne
    Roy, Ananya
    Liu, Yanfang
    Perini, Rodolfo F.
    Linehan, W. Marston
    Jonasch, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Phase II study of the oral hypoxia-inducible factor 2[alpha] (HIF-2[alpha]) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
    Iliopoulos, Othon
    Jonasch, Eric
    Donskov, Frede
    Narayan, Vivek
    Maughan, Benjamin Louis
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah J.
    Thamake, Sanjay
    Perini, Rodolfo F.
    Park, Eric Kristopher
    Linehan, Marston W.
    Srinivasan, Ramaprasad
    Rathmell, Kimryn W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [47] Phase II study of the oral HIF-2a inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease
    Srinivasan, R.
    Donskov, F.
    Iliopoulos, O.
    Rathmell, W. K.
    Narayan, V. K.
    Maughan, B. L.
    Oudard, S.
    Else, T.
    Maranchie, J. K.
    Welsh, S. J.
    Thamake, S.
    Park, E. K.
    Perini, R. F.
    Linehan, W. M.
    Jonasch, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S1158 - S1158
  • [48] LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data.
    Jonasch, Eric
    Iliopoulos, Othon
    Rathmell, Wendy Kimryn
    Narayan, Vivek
    Maughan, Benjamin L.
    Oudard, Stephane
    Else, Tobias
    Maranchie, Jodi K.
    Welsh, Sarah Joanne
    Iversen, Ane Bundsbaek Bondergaard
    Roy, Ananya
    Liu, Yanfang
    Perini, Rodolfo F.
    Linehan, W. Marston
    Srinivasan, Ramaprasad
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Disturbed Flow Increases UBE2C (Ubiquitin E2 Ligase C) via Loss of miR-483-3p, Inducing Aortic Valve Calcification by the pVHL (von Hippel-Lindau Protein) and HIF-1 (Hypoxia-Inducible Factor-1) Pathway in Endothelial Cells
    Esmerats, Joan Fernandez
    Villa-Roel, Nicolas
    Kumar, Sandeep
    Gu, Lina
    Salim, Md Tausif
    Ohh, Michael
    Taylor, W. Robert
    Nerern, Robert M.
    Yoganathan, Ajit P.
    Jo, Hanjoong
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (03) : 467 - 481